![2020 05 19 23 52 8693 2020 05 20 Hepatitis D 400](https://img.labpulse.com/files/base/smg/all/image/2020/05/lp.2020_05_19_23_52_8693_2020_05_20_Hepatitis_D_400.png?auto=format%2Ccompress&q=70&w=400)
Patients with hepatitis B should be also be screened for hepatitis D, as coinfection puts them at greater risk for liver cancer, according to a study set to be published in an upcoming issue of the Journal of Hepatology
A review of the literature suggests that those who have hepatitis D along with hepatitis B have up to three times the risk for developing hepatocellular carcinoma than if they had hepatitis B alone, reported researchers at the University of Geneva and Geneva University Hospitals, in an article in press. This assessment was based on an analysis of data from 93 studies including a total of more than 100,000 patients.
![Microscopic image of hepatocellular carcinoma](https://img.labpulse.com/files/base/smg/all/image/2020/05/lp.2020_05_19_23_29_8435_2020_05_20_Hepatitis_D_20200519234657.png?auto=format%2Ccompress&fit=max&q=70&w=400)
Hundreds of millions of people have hepatitis B worldwide. It's unclear how many also have hepatitis D -- estimates range from 15 million to 60 million as systematic testing has been lacking, the authors noted in a statement released by the University of Geneva. The review suggests a need for systematic screening of hepatitis B patients for hepatitis D due to the heightened risk for cancer, concluded Dr. Francesco Negro, professor of pathology and immunology at the University of Geneva, and colleagues said in a statement on May 18. Results were initially published online on March 26.